Навигация
X

Литература к теме: «Актуальные дискуссионные вопросы диагностики, классификации, нейропатологии, патогенеза и терапии шизофрении»

Полный список литературы

  1. Гофман А.Г. (ред.) Психиатрия. Справочник практического врача. М, «Медпрессинформ», 2006,591 с.
  2. Гризингер В. Душевные болезни. Спб., 1886.
  3. Джонс П., Бакли П. Шизофрения. М., «Медпрессинформ», 2008,192 с.
  4. Жислин С. Г. Очерки клинической психиатрии. М., «Медицина», 1965, 320 с.
  5. Зейгарник Б. В. Патология мышления, М., 1962, 244 с.
  6. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция негативных и позитивных расстройств. М., «Новый цвет», 2001, 238 с.
  7. Поляков Ю. Ф. Патология познавательной деятельности при шизофрении. — М., «Медицина» 1974,168 с.
  8. Снежневский А. В. (ред.) Руководство по психиатрии, Т. 1, М. «Медицина», 1983, с. 299.
  9. Тиганов А. С. (ред.) Руководство по психиатрии, Т. 1, М. «Медицина», 1989.
  10.  Уотсон Д. ДНК и мозг (в поисках генов психических заболеваний). Лекция 3 июля 2008 г. в г. Москве, http://elementy.ru/lib/430639.
  11. Alder С.М., Strakowski, S.M. Boundaries of schizophrenia//Psychiatr. Clin.N. Am., 2003, Vol. 26, p. 1-23
  12. Ahmed A., Iqbal E., Fujii V., Daryl M. The spectrum of psychotic disorders: neurobiology, etiology, and pathogenesis//Cambridgc, UK: Cambridge University Press, 2007.
  13. Alkelai A., Baum A., Carless M. et al. The XVth World Congress of Psychiatric Genetics, October 7-11, Rapporteur summaries of oral presentations//Am.J. Med. Genet. Part B. Neuropsychiatr. Genet., 2008, Vol. 147B, p. 233-277.
  14. Andreasen N.C. Negative symptoms in schizophrenia//Arch. Gen. Psychiatry, 1982, Vol. 39, p. 784-788.
  15. Andreasean N.C. Symptoms, signs and diagnosis of schizophrenia//Lancet, 1995, Vol. 346, p. 477-481.
  16. Andreasen N.C. Schizophrenia: the fundamental questions//Brain Res. Brain. Res. Rev., 2000, Vol. 31, p. 106-112.
  17. Arts B., Jabben N., Krabbendam L. et al. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives//Psychol. Med., 2008, Vol. 38, p. 771-85.
  18. Awad A. G., Voruganti L.N. The burden of schizophrenia on caregivers: a review//Pharmacoeconomics, 2008, Vol. 26, № 2, p. 149-162.
  19. Bartzokis G., Lu P.H., Nuechterlein K.H. et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia//Schizophr. Res., 2007, Vol. 93, p. 13-22.
  20. Benes F. M., Davidson J., Bird E. D. Quantiative cytoarchitectural studies of the cerebral cortex of schizophrenics//Arch. Gen. Psychiatry, 1986, Vol. 43, № 1, p. 31-35.
  21. Berridge К. C., Robinson T. E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?//Brain Res Brain Res. Rev., 1998, Vol. 28, p. 309-369.
  22. Bitanihirwe В. K., Woo T. U. Oxidative stress in schizophrenia: an integrated approach//Neurosci. Biobehav. Rev., 2011, Vol. 35, № 3, p. 878-893.
  23. Bora A. et al. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond//Schizophren. Bull., 2010, Vol. 36, p. 36-42.
  24. Brown R., Colter N., Corsellis J. A. et al. Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahyppocampal gyrus compared with affective disorders//Arch. Gen. Psychiatry, 1986, Vol. 43, p. 36-42.
  25. Buchanan R. W., Carpenter W.T., Schizophrenia. Introduction and overview./Kaplan B., Sadock V. (eds.) Comprehensive textbook of psychiatry. 7th edition, Vol. I., Philadelphia, Lippincott, Williams and Wilkins. 2000, p. 1096-1110.
  26. Buckholtz J. W., Callicott J. H., Kolachana B. et al. Genetic variation in MAOA modulates ventromedial prefrontal circuity mediating individual differences in human personality//Mol. Psychiatry, 2008, Vol. 13, № 3, p. 313-324.
  27. Cahn W., Pol H. E., Lems E. B., van Haren N. E. et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study//Arch. Gen. Psychiatry, 2002, Vol. 59, p. 1002-1010.
  28. Cahn W., van Haren N.E., Hulshoff Pol H. E. et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia//Br. J. Psychiatry, 2006, Vol. 189, p. 381-382.
  29. Callicott J. H., straub R. E„ Pezawas L. et al. Variation in DISCI affects hippocampal structure and function and increases risk for schizophrenia//Proc. Natl. Acad. Sci USA, 2005, Vol. 102, № 24, p. 8627-8632.
  30. Campaign for The Abolition of The Schizophrenia Label (http://www/caslcampaign.com/).
  31. Cannon T. D., Hennah W., van Erp T. G. et al. Association of DISC1/TRAX halotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory//Arch. Gen. Psychiatry, 2005, Vol. 62, № 11, p. 1205-1213.
  32. Cannon T. D., Huttunen M. O., Dahlstrom M. et al. Antipsychotic drug treatment in the prodromal phase of schizophrenia//Am. J. Psychiatry, 2002, Vol. 159, № 7, p. 1230 -1232.
  33. Cannon T. D., Cadenhead K., Cornblatt B. et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America//Arch. Gen. Psychiatry, 2008, Vol. 65, p. 28-37.
  34. Cardno A. G., Marshall E. J., Coid B. et al. Heritability estimated for psychotic disorders: the Maudsley twin psychosis series//Arch. Gen. Psychiatry, 1999, Vol. 56, p. 162-168.
  35. Carlsson A. The current status of the dopamine hypothesis of schizophrenia//Neuropsychopharmacology, 1988, Vol. l,p. 179-186.
  36. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson’s disease (review)//Trends. Neurosci., 1990, Vol. 13, p. 272-276.
  37. Carpenter W. T. Anticipating DSM-V: should psychosis risk become a diagnostic class?/Schizophr. Bull., 2009, Vol. 35, p. 841-843.
  38. Chakos M.H., Lieberman J. A., Alvir J. et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine//Lancet, 1995, Vol. 345, p. 456-457.
  39. Cheniaux E., Landeira-Fernandez J., Lessa Telles L. et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders//J. Affect. Disord., 2008, Vol. 106, p. 209-217
  40. Chubb J.E., Bradshaw D.C., Soares D.J. et al. The DISC locus in psychiatric illness//Mol. Psychiatry, 2008, Vol. 13, p. 36-64.
  41. Cochrane Library, Meta-analyses on the efficacy of different drugs and interventions in schizophrenia (up to September 2011).
  42. Collier D. A. Schizophrenia: the polygene princess and the pea//Psychol. Med., 2008, p. 1-5.
  43. Compton M. T. Considering schizophrenia from a prevention perspective//Am. I. Prev. Med., 2004, Vol. 26, p. 178-185.
  44. Costa E., Dong E., Grayson D. R. et al. Epigenetic targets in GABAergic neurons to treat schizophrenia//Adv. Pharmacol., 2006, Vol. 54, p. 95-117.
  45. Crespi Psychosis and autism as diametrical disorders of the social brain (http://www. bbsonline.org/Preprints/Crespi-02162007).
  46. Crow T.J. The two syndrome concept, origins and current status//Schiz. Bull., 1985, Vol. 1L p. 471-477.
  47. Crow T.J. How and why genetic linkage has not solved the problem of psychosis: review and hypothesis/Am. J. Psychiatry, 2007, V. 164, p. 13-21.
  48. Crow T.J. The emperors of the schizophrenia polygene have no clothes//Psychol.Med., 2008, p. 1-5.
  49. Cuesta M. J., Peralta V., Zarzuela A. Empirical validation of competing definitions of schizophrenia: a polydiagnostic study of cognitive impairment in non-affective psychosis//Schizophr. Res., 2007, Vol. 95, p. 39-47.
  50. Davis J., Chen N., Glick I. D. A meta-analysis of the efficacy of second-generation antipsychotics//Arch. Gen Psychiat., 2003, Vol. 60, № 6, p. 553-64.
  51. Davis K. L., Stewart D. G., Friedman J. I. et al. White-matter changes in schizophrenia: evidence for myelin-related dysfunction//Arch. Gen. Psychiatry, 2003, Vol. 60, p. 443-456.
  52. Deister A., Marneros A. Long term stability of subtypes in schizophrenia disorders: a comparison of four diagnostic systems//Eur. Arch. Psychiatry Clin. Neurosci., 1992, Vol. 242, p. 184-190
  53. DeLisi L. E., Friedrich U., WahlstrowJ. et al. Schizophrenia and sex chromosome anomalies//Schizophr. Bull., 1994, Vol. 20, p. 495-505.
  54. DeLisi L. E., Shaw S. H., Crow T.J. et al. A genome-wide san for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder//Am. J. Psychiatry, 2002, Vol. 159, p. 803-812.
  55. Deutsch S.I., Mastropaolo J., Schwartz B. L. et al. A «Glutamatergic hypothesis» of schizophrenia//Clin. Neuropharmacol., 1989, Vol. 12, p. 1-13.
  56. Dierks T., Linden D. E., Jandl M. et al. Activation of Heschl’s gyrus during auditory hallucinations//Neuron, 1999, Vol. 22, p. 615-621.
  57. Do K. Q., Bove T. P, Cuenod M. Schizophrenia: glutathione deficit as a new vulnerability factor factor for disconnectivity syndrome//Schweizer Archiv Neurol. Psychiat., 2004, Vol. 155, № 8, p. 375-385.
  58. Dysfunctional Perception Syndrome (http://astridvanwoerkom.wordpress. com/2009/10/09/schizophrenia-now-called-dysfunctional-perception-syndrom/)
  59. Duan J., Martinez M., Sanders A. R. et al. DTNBP1 and schizophrenia: association evidence in the 3’end of the gene//Hum. Hered., 2007, Vol. 64, p. 97-106.
  60. Fanous A. H., Kendler K. S. Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature//Current Psychiatry Reports, 2008, Vol. 10, p. 164-170
  61. Faraone S. V, Seidman I.J., Kremen W.S. et al. Neuropsychologic functioning among the nonspecific relatives of schizophrenic patients: a four-year follow up study//J. Abnorm. Psychol., 1999, Vol. 108, p. 176-181.
  62. Feinberg I. Efference copy and corollary discharge: implications for thinking and its disorders//Schizophr. Bull., 1978, Vol. 4, p. 636-640.
  63. Fenton W. S., McGlashan T. H. Natural history of schizophrenia subtypes. 1. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia//Arch. Gen. Psychiatry, 1991, Vol. 48, p. 969-977
  64. FiedorowiczJ.G., Epping E. A., Flaum M. Toward defining schizophrenia as a more useful clinical construct//Curr. Psychiatry Rep., 2008, Vol. 10, p. 344-351
  65. Ford J. M., Mathalon D. H. Corollary discharge dysfunction in schizophrenia: can it explain auditory hallucination?//Int.J. Psychophysiol., 2005, Vol. 58, p. 179-189.
  66. Frith C. D., Done D.J. Towards a neuropsychology of schizophrenia//Br.J. Psychiatry, 1988, Vol. 153, p. 437-443.
  67. Frith C. D., Friston K. J., Liddle P. F., Frackowiak R. S. A PET study of word finding//Neuropsychologia, 1991, Vol. 29, p. 1137-1148.
  68. Frith C. D., Blakemore S., Wolpert D. M. Explaining the symptoms of schizophrenia: abnormalities in the awareness of action//Brain Ress., 2000, Vol. 31, № 2-3, p. 357-363.
  69. Jackson J. H. Selected writings. Holder and Stoughton, London, 1931, Vol. 1, p. 411.
  70. Javitt D. C., Zukin S. R. Recent advances in the phencyclidine model of schizophrenia//Am.J. Psychiatry, 1991, Vol. 148, p. 1301-1308.
  71. Geddes J., Freemantle N., Harrison P. et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and regression analysis//BMJ, 2000, № 321, p. 1371-76.
  72. Gogtay N., Gied J.N., Lusk L. et al. Dynamic mapping of human cortical development during childhood through early adulthood//Proc. Natl. Acad. Sci. USA, 2004, Vol. 101, № 21, p. 8174-8179.
  73. Goldberg T. E., Straub R. E., Callicott J. H. et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia//Neuropsychopharmacology, 2006, Vol. 31 (9), p. 2022-2032.
  74. Green M. E, Kern R. S., Heaton R. K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS//Schizophr. Res., 2004, Vol. 72, № 1, p. 41-51.
  75. Griesinger W. Die Pathologic und Therapie der psychischen Krankheiten. Braunsduweig: Verlag von Friedrich Wreden, 1871, 53-85.
  76. Hafner H., van der Heinden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies//Eur. Arch. Psychiatry, Clin. Neurosci., 1999, Vol. 249, Suppl. 4, p. 14-26.
  77. Hall J., Whalley H. C., Job d. E. et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms//Nat. Neurosci, 2006, Vol. 9(12), p. 1477-1478.
  78. Hanninen k., Katila H., Saarela M. et al. Interleukin-1 beta gene polymorphism and its interactions with neuroregulin-1 gene polymorphism are associated with schizophrenia//Eur. Arch. Psychiatry Clin. Neurosci., 2008, Vol. 258, p. 10-15.
  79. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation//Brain, 1999, Vol. 122, p. 593-624.
  80. Heckers S. Who is at risk for a psychotic disorder?//Schizophr. Bull., 2009, Vol. 35, p. 847-850.
  81. Heckers S. Is schizoaffective disorder a useful diagnoses?//Curr. Psychiatry Res., 2009, Vol. 13, p. 332-337
  82. Heidrich A., Strik W. K. Auditory P300 topography and neuropsychological test performance: evidence for left hemispheric dysfunction in schizophrenia//Biol. Psychiatry, 1999, Vol. 41, p. 327-335.
  83. Heinrichs R. W. The primacy of cognition in schizophrenia//Am. Psychol., 2005, Vol. 60 (3), p. 229-242.
  84. Helmes E., Landmark J. Subtypes of schizophrenia: a cluster analytic approach//Can. J. Psychiatry, 2003, Vol. 48, p. 702-708
  85. Hempel C.G. Introduction to problems of taxonomy//In Hempel С/G/, Zubin J., editors. Field Studies in the Mtntal Disoders. New York: Grune&Stratton; 1961, p. 3-22.
  86. Hemsley D. R., Zawada S. L. «Filtering» and the cognitive deficit in schizophrenia//Br.J. Psychiatry, 1976, Vol. 128, p. 456-461.
  87. Henquet C., Di Forti M., Morrison P. et al. Gene-Environment Interplay Between Cannabis and Psychosis//Schizophr. Bull., 2008, Vol. 34, № 6, p. 1111-1121.
  88. Hill S. K., Keshavan M. S., Thase M. E. et al. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression//Am.J. Psychiatry, 2004, Vol. 161, № 6, p. 996-1003.
  89. Hoche A. Die Medizin der Gegenwart in Sellbstdarstellungen, 1925.
  90. Honea R., Crow T.J., Passingham D., et al., Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies//Am. J. Psychiatry, 2005, Vol. 162, № 12, p. 2233-2245.
  91. Huber G. Schizophrenia and Cyclothymia, the results and problems//Stuttgart, 1969.
  92. Huber G. Das Konzeptsubstratnaher Basis Symptome und seine Bedeutungfiir Theorie und Therapieschizophrener Erkrankungen//Nervenarzt, 1982, Vol. 54, № 1, p. 23-32.
  93. Huber G. Konzept substratnaher Basis Symptome und seine Bedentung fur Theorie und Therapie Schizophrener Erkrankungen//Nervenarrt, 1982, Bd.54, № 1, S. 23-32.
  94. Ivleva E. I., Morris D.W., Moaters A E et al. Genetics and intermediate phenotypes of the schizophrenia — bipolar disorder boundary//Neurosci. Biobehav. Rev., 2010, Vol. 34, p. 897-921
  95. Jablensky A. Subtyping schizophrenia: implications for genetic research//Mol Psychiatry, 2006, Vol. 11, p.815-836
  96. Jager M., Bottlender R., Strauss A., Moller H.J. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders//Acta Psychiatry Scand., 2004, Vol. 109, p. 30-37
  97. Janzarik W. The Types of schizophrenia. Berlin, Heidelberg, New-York, 1968.
  98. Janzarik W. SchizophreneVerlaufe. Heidelberg, New York, 1968.
  99. Jones P. B., Barnes T. R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)//Arch. Gen. Psychiatry, 2006, Vol. 63, p 1079-1087.
  100. Kahn R. S., Fleischhacker W. W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial//Lancet 2008, Vol. 371, p. 1085-1097.
  101. Kaplan B., Sadock V. Handbook of clinical psychiatry. 4th ed., Williams, Wilkins, 1998,505 p.
  102. Kapur S. Psychosis as a state of aberrant salience: a framenork linking biology, phenomenology, and pharmacology in schizophrenia//Am.J. Psychiatry, 2003, Vol. 160, № 1, p. 13-23.
  103. Kapur S., Mizrahi M., Li M. From dopamine to salience to psychosis — linking biology, pharmacology and phenomenology of psychosis//Schizophrenia Research, 2009, Vol. 79, № 1, p. 59-68.
  104. Kay S. R., Singh M. M. Cognitive abnormality in schizophrenia: A dual process model//Biol. Psychiat, 1979, Vol. 14, p. 155-176
  105. Keefe R. S., Eesley С. E., Poe M. P. Defining a cognitive function decrement in schizophrenia//Biol. Psychiatry, 2005, Vol. 57, № 6, p. 688-692.
  106. Keefe R. S., Fenton W. S. How should DSM-V criteria for schizophrenia include cognitive impairment?//Schizophr. Bull., 2007, Vol. 33, № 4, p. 912-920.
  107. Kendell R. E., Brockington I. F. The identification of disease entities and the relationship between schizophrenia and affective psychoses//Br.J. Med. Bull., 1980, Vol. 137, p. 324-331
  108. Kendler K. S., Gruenberg A. M., Tsuang M.T. A family study of the subtypes of schizophrenia//Am.J. Psychiatry, 1980, Vol. 145, p. 57-62
  109. Keshavan M.S., Nasrallah H. A., Tandon R. Schizophrenia, «Just the facts» 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse//Schizophrenia Res., 2011, Vol. 127, p. 3-13.
  110. KimJ.S., Kornhuber H.H., Schmid-Burgk W., Holzmiiller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia//Neurosci. Lett., 1980, Vol. 20, p. 379-382.
  111. Kirkpatrick B., Buchanan R. W., Ross D.E., Carpenter W.T. A Separate Disease within the Syndrome of Schizophrenia//Arch. Gen. Psychiatry, 2001, Vol. 58, p. 165-171.
  112. Kishimoto T., Agarwal V., Kishi T. et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics//Mol. Psychiatry, 2011.
  113. Klosterkotter J., Schultze-Lutter E, Ruhrmann S. Kraepelin and psychotic prodromal conditions//Eur. Arch. Psychiatry Clin. Neurosci., 2008, Vol. 258, Suppl. 2, p. 74-84.
  114. Konrad A., Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?//Schizophr. Bull., 2008, Vol. 34, p. 72-92.
  115. Krebs M., Leopold K., Hinzpeter A. et al. Neuroprotective agents in schizophrenia and affective disorders//Expert Opin Pharmacothcr, 2006, Vol. 7, № 7, p. 837 -848.’
  116. Kubicki m., McCarley R., Westin C. F. et al. A review of diffusion tensor imaging studies in schizophrenia//J. Psychiatr. Res., 2007, Vol. 41, p. 15-30.
  117. Lee C., McGlashan T. M., Woods S. W. Prevention of schizophrenia: can it be achieved?//CNS Drugs, 2005, Vol. 19, p. 193-206
  118. Lehman A. E, Kreyenbuhl J., Buchanan R. W. et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations//Schizophrenia Bull., 2004, Vol. 30, №2,. p. 193-217.
  119. Leucht S., Barnes T. R., Kissling W., et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review of exploratory meta-analysis of randomized, controlled trials//Am. J. Psychiat., 2003, Vol. 160, № 7, p. 1209-22.
  120. Leucht S., Corves C., Arbter D., Engel R., Li C., Davis J. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis//Lancet, 2009, Vol. 373, p. 31-41.
  121. Leucht S., Komossa K., Pummel-Kluge C. et al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia//Am. J. Psychiatry, 2009, Vol. 166, p. 2.
  122. Lewandowski К. E. Relationship of catechol-O-methyltransferase to schizophrenia and its correlates: evidence for associations and complex interactions//Harv. Rev. Psychiatry, 2007, Vol. 15, p. 233-244.
  123. Lewis D. A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders//Neuropsychopharmacology, 2002, Vol. 26, p. 143-144.
  124. Lewis D. A., Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons//Int. Rev. Neurobiol., 2007, Vol. 78, p. 109-131.
  125. Lieberman J. A., Stroup T.S., McEvoyJ.P. et al. Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia//The New England Journal of Medicine, 2005, Vol. 353, № 12, p. 1209-1223.
  126. Lieberman J. A., Tollefson G. D., Charles C. et al. Antipsychotic drug effects on brain morphology in first-episode psychosis//Arch. Gen. Psychiatry, 2005, Vol. 62, p. 361-370.
  127. Lieberman J. A., Perkins D. O., Jarskog L. F. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia//CNS Spectr., 2007, Vol. 12, № 3 suppl. 4, p. 1-13.
  128. Lim K.O., Helpern J. A. Neuropsychiatric applications of DTI — a review//NMR Biomed., 2002, Vol. 15, p. 587-593.
  129. Markova E., Okhotin V, Mosolov S. et al. The similarity of degenerative changes in the dendrites of olfactory tubercle spiny neurons in schizophrenia and basal forebrain reticular neuron in Alzheimer disease//The World Jour. Biol. Psychiatry, 2001, Vol. 2, Suppl. 1, p. 38.
  130. McCarthy S. E., Makarov V, Kirov G. et al. «Microduplications of 16pl 1.2 are associated with schizophrenia»//Nature Genetics, 2009, Vol. 41, N2 11, p. 1223-1227.
  131. McGlashan T. H., Zipursky R. B., Perkins D. et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis//Am. J.. Psychiatry, 2006, Vol. 163, № 5, p. 790-799.
  132. McGlashan T. H., Addington J., Cannon T. et al. Recruitment and treatment practices for help-seeking «prodromal» patients//Schizophr. Bull., 2007, Vol. 33, № 3, p. 715-726.
  133. McClellan J. M., Susser E., King M. C. Schizophrenia: a common disease caused by multiple rare alleles//British Journal Psychiatry, 2007, № 3, Vol. 190, p. 194-199.
  134. Me Evoy M. et al. Poster presented at Annual New Clinical Drug Evaluation Unit Meeting, June 12-16, 2006, Boca Raton, Florida, USA.
  135. McGorry P.D., Allot K., Jackson H.J. Diagnosis and the staging model of psychosis//The recognition and management of early psychosis/eds. H.J. Jackson, P. D. McGorry, Cambtidge University Press., 2010, p. 17-27.
  136. McGorry P. D., Yung A. R., Phillips L.J. et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms//Arch. Gen. Psychiatry, 2002, Vol. 59, № 10, p. 921-928.
  137. McGorry P. D., Yung A. R., Bechdolf A. et al. Back to the future: predicting and reshaping the course of psychotic disorder//Arch. Gen. Psychiatry, 2008, Vol. 65, № 1, p. 25-27.
  138. Meyer-Lindenberg A.S., Olsen R.K. et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia//Arch. Gen. Psychiatry, 2005, Vol. 61, p. 379-386.
  139. Molina V, Sanz J., Sarramea F. et al. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients//Psychiatry Res., 2004, Vol. 131, № 1, p. 45-56.
  140. Molina V, Reig S., Sanz J. et al. Increase in Gray Matter Volume and Decrease in White Matter Volume in the Cerebral Cortex during Treatment with Atypical Neuroleptics in Schizophrenia//Eur.J. Psychiat., 2005, Vol. 19, №.4 http://dx.doi. org/10.4321/S0213-61632005000400004
  141. Moore T. H. M., Zammit S., Lingford-Hughes A. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review//Lancet., 2007, Vol. 370, p. 319-328.
  142. Muller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders//Eur. Arch. Psychiatry Clin. Neurosci., 2008, Vol. 258, Suppl. 2, p. 97-106.
  143. Munafo M. R., Atwood A. S., Flint J. Neuregulin 1 genotype and schizophrenia//Schizophr. Bull., 2008, Vol. 34, p. 9-12.
  144. Murray R., 2008 (personal communication).
  145. Murray R. M., Sham P, Van Os J. et al. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder//Schizophr. Res., 2004, Vol. 71, p. 405-16.
  146. Nakamura M., Salisbury D. E, Hirayasu Y. et al. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study//Biol. Psychiatry, 2007, Vol. 62, № 7, p. 773-783.
  147. Nasrallah H. A., Keshavan M.S., Benes F. M. et al. Proceedings and Data From The schizophrenia Summit: a clinical appraisal to improve the management of schizophrenia//J. Clin. Psychiatry, 2009, Vol. 70, Suppl. 1, p. 4-46.
  148. Nasrallah H. A. The unintegrated right cerebral hemispheric consciousness as alien intruder: a possible mechanism for Schneiderian delusions in schizophrenia//Compr. Psychiary, 1985, Vol. 26, p. 273-282.
  149. National Collaborating Centre for Mental Health: Schizophrenia. Full national clinical guidelines on core interventions in primary and secondary care. London, Gaskell and British Psychological Society, 2003, 252 p.
  150. Nicodemus K.K., Kolachana B.S., Vakkalanka R. et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms inRGS4, G72, GRM3 and DISCI: influence on risk of schizophrenia//Hum. Genet., 2007, Vol. 120, p. 889-906.
  151. O’Donovan M. C., Cradock N., Owen M.J. Schizophrenia: complex genetics, not fairy tales//Psychol. Med., 2008, p. 1-3.
  152. Owen M. J., Craddock N., Jablensky A. The genetic deconstruction of psychosis//Schizophr. Bull., 2007, Vol. 33, p. 905-11.
  153. ParnasJ., Bovet R, Innocenti G.M. Schizophrenic trait features, binding, and cortico-cortical connectivity: a neurodevelopmental pathogenetic hypothesis//Neurology, Psychiatry and Brain research, 1996, Vol. 4, p. 185-196.
  154. PeralaJ., SuvisaariJ., Saarni S. I. et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population//Arch. Gen. Psychiatry, 2007, Vol. 64, p. 19-28
  155. Peralta V, Cuesta M.J. Diagnostic significance of Schneider’s first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders//Br.J. psychiatry, 1999, Vol. 174, p. 243-248.
  156. Peralta V, Cuesta M.J. How many and which are the psychological dimensions of schizophrenia//Schizophr. Bull., 2007, Vol. 33, p. 905-911.
  157. Petronis A., Paterson A. D., Kennedy J. L. Schizophrenia: an epigenetic Puzzle?//Schizophr. Bull., 1999, Vol. 25, p. 639-655.
  158. Purcell S. M., Wray N. R., Stone J. L. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder//Nature, 2009, Vol. 460, № 8, p. 748-752.
  159. Purves D., Fugustine G.J., Fitzpatrick D. et al. Neuroscience. 2nd edition. Sunderland: Sinauer; 2001, p. 406.
  160. Rcgicr D. A. Time for a fresh start? Rethinking psychosis in DSM-V//Schizophr Bull., 2007, Vol. 33, p. 843-845.
  161. Rizzolatti G., Fadiga L., Gallese V, Fogassi L. Premotor cortex and the recognition of motor actions//Brain res. Cogn. Brain Res., 1996, Vol. 3, № 2, p. 131-141.
  162. Rosenheck R., Perlick D., Bingham S. et al. European First Episode Trial (EUFEST) comparing Ziprazidone, Amisulpride, Quetiapine, Olanzapine and Haloperidol in a randomized open-label one-year design//Lancet, 2007, Vol. 356, p. 1344-1350.
  163. Rossler W., Salize H.J., Van Os J. et al. Size of burden of schizophrenia and psychotic disorders//Eur. Neuropsychopharmacol., 2005, Vol. 15, № 4, p. 399-409.
  164. Ruhrmann S., Schultze-Lutter E, Salokangas R. K. et al. Prediction of psychosis in adolescents and young adults at high risk: results from the Prospective Prediction of Psychosis Study//Arch. Gen. Psychiatry, 2010, Vol. 67, p. 241-251.
  165. Rund B. R. A review of longitudinal studies of cognitive functions in schizophrenia patients//Schizophr. Bull., 1998, Vol. 24, p. 425-435.
  166. Sanders A. R., DuanJ., Levinson D. F. et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics//Am.J. Psychiatry, 2008, Vol. 165, p. 497-506.
  167. Sato M. Renaming schizophrenia: a Japanese perspective//World Psychiatry, 2006, Vol. 1, p. 53-55.
  168. Saykin A.J., Gur R. C., Gur R. E. et al. Neuropsychological function decrement in schizophrenia: selective impairment in memory and learning//Arch. Gen psychiatry, 1991, Vol. 48, No 7, p. 618-624.
  169. Schwab S. G., Plummer C., Albus M. et al. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study//Psychiatr. Genet., 2008, Vol. 18, p. 25-30.
  170. Selemon L.D., Rajkowska G., Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17//Arch. Gen. Psychiatry, 1995, Vol. 52, № 10, p. 805-818.
  171. Selemon 1. D., Goldman-Rakic P. S. The reduced neuropil hypothesis: a circuit-based model of schizophrenia (review)//Biol. Psychiatry, 1999, Vol. 45, p. 17-25.
  172. Semple D. M., McIntosh A. M., Lawrie S. M. Cannabis as a risk factor for psychosis: systematic review//J. Psychopharmacol., 2005, Vol. 19, p. 187-194.
  173. Schenkel L.S., Silverstein S.M. Dimensions of premorbid functioning in schizophrenia: a rewiew of neuromotor, cognitive, social, and behavioral domains//Genetic, Social and General. Psychol. Monogr., 2004, Vol. 130, p. 241-270.
  174. Schwartz R. S., Fennig S., Tenenberg-Karant M., Carlson G., et al. Congruence of diagnoses 2 years after first-admission diagnosis of psychosis//Arch. Gen. Psychiatry, 2000, Vol. 38, p. 283-288
  175. Snitz В. E., Macdonald A. W. 3rd, Carter C. S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes//Schizophr. Bull., 2006, Vol. 32, № 1, p. 179-194.
  176. Spalletta G., Tomaiuolo F., Marino V et al. Chronic schizophrenia as a brain misconnection syndrome: a white matter voxel-based morphometry study//Schizophr. Res., 2003, Vol. 64, № 1, p. 15-23.
  177. Spencer К. M., Nestor P. G., Niznikiewicz M. A. et al. Abnormal neural synchrony in schizophrenia//J. Neurosci., 2003, Vol. 23, p. 7407-7411.
  178. Stephan K. A., Baldeweg T., Friston K.J. Synaptic plasticity and disconnection in schizophrenia//Biol. Psychiatry, 2006, Vol. 59, p. 929-939.
  179. Straub R. E., Lipska В. K., Egan M. F. et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and expression//Mol. Psychiatry, 2007, Vol. 12, № 9, p. 854-869.
  180. Strauss J. S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia: III. Speculations on the process that underlie schizophrenic symptoms and signs//Schizophr. Bull., 1974, Vol. 11, p. 61-76.
  181. Sullivan P. F. The dice are rolling for schizophrenia genetics//Psychol. Med., 2008, p. 1-4.
  182. Sullivan P. E, Kendler K. S., Neale M. C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies//Arch. Gen. Psychiatry, 2003, Vol. 60, p. 1187-1192.
  183. Siillwold L. Symptome schizophrener Erkrankungen. Uncharakteristische Basisstorungen.-Mongraphien ans dem Gesamtgebiete der Psychiatrie. Bd.13, Berlin, 1977.
  184. Suvisaari J., PeralaJ., Saarni S. I., et al. The epidemiology and descriptive and predictive validity of DSN-IV delusional disorder and subtypes of schizophrenia//Clin. Schizopr. Related Psychology, 2009, Vol. 2, p. 289-297
  185. Talkowski M. E., Kirov G., Bamne M. et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia//Hum. Mol. Genet., 2008, Vol. 17, p. 747-758.
  186. Tan H. Y., Nicodemus К. K., Chen Q. et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans//J. Clin. Invest, 2008, Vol. 118, № 6, p. 2200-2208.
  187. Tandon R., Greden. F. Cholinergic hyperactivity and negative schizophrenic symptoms//Arch. Gen Psychiatry, 1989, Vol. 46, p. 745-753.
  188. Tandon R., Keshavan M.S., Nasrallah H. A. Schizophrenia, «Just the facts»: What we know in 2008, Part 1: Overview//Schizophr. Res., 2008, Vol. 100, p. 4-19.
  189. Tandon R., Belmaker R. H., Gattaz W. F. et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia//Schizophr Res, 2008, Vol. 100, p. 20-38.
  190. Tandon R., Maj M. Nosological status and definition of schizophrenia: some considerations for DSM-V and ICD-ll//AsianJ. Psychiatry, 2008, Vol. 1, p. 22-27.
  191. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, «just the facts». 4. Clinical feature and conceptualization//Schizophr. Res., 2009, Vol. 110, p. 1-23.
  192. Tandon R., Keshavan M. S., Nasrallah H. A. Schizophrenia, «Just the facts»: What we know in 2008, Part 2: Epidemiology and etiology//Schizophr. Res., 2008, Vol. 102, p. 1-18.
  193. Tandon R., Keshavan M. S., Nasrallah H. A. Schizophrenia, «Just the facts»: Treatment and prevention. Past, present and future//Schizophr. Res., 2010, Vol. 122, p. 1-23.
  194. Taylor M. A., Shorter E., Vaidya N. A., Fink M. The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition//Acta Psychiatr. Scand , 2010, Vol. 122, p. 173-183.
  195. Tsuang M.T., Faraone S. V. The case for heterogeneity in the etiology of schizophrenia//Schizopr. Res., 1995, Vol. 17, p. 161-175.
  196. Tunbrige E.M., Harrison P.J., Weinberger D. R. Catechol-O-menthyltransferase, cognition, and psychosis: Vall58Met and beyond//Biol. Psychiatry, 2006, Vol. 60, № 2, p. 141-151.
  197. Umbricht D., Schmid L., Koller R. et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia//Arch. Gen. Psychiatry, 2000, Vol. 57, p. 1139-1147.
  198. UranovaN. A., Orlovskaya D.D., Vikhreva O. Electron microscopy of oligodendroglia in severe mental illness//Brain Res. Bull., 2001, Vol. 55, p. 597-610.
  199. Van der Does A.J. W., Linszen D. H., Dingemans, P. M.A.J. et al. A dimensional and categorical approach to the symptomatology of recent-onset schizophrenia//J Nerv. Ment. Dis., 1993, Vol. 181, p. 744-749.
  200. Van Haren N. E., Hulshoff Pol H. E., Schnack H. G. et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study//Neuropsychopharmacology, 2007, Vol. 32, Nb 10, p. 2057-2066.
  201. Van Os J. Is there a continuum of psychotic experiences in the general population?//Epidemiol. Psychiatr. Soc., 2003, Vol. 12, p. 242-252
  202. Van Os J. Salience syndrome replaces schizophrenia in DSM-V and ICD-11: psychiatry’s evidence-based entry into the 21st century?//Acta Psychiatr. Scand., 2009, Vol. 120, № 5; p. 72-363.
  203. Van Os J. A salience dysregulation syndrome//Br. J. Psychiatry, 2009, Vol. 194, № 2, p. 3-101.
  204. Van Os .J., Delespaul P. Toward a world consensus on prevention of schizophrenia//Dialogues Clin. Neurosci, 2005, № 7, p. 53-67
  205. Van Os J, Kapur S. Schizophrenia//Lancet, 2009, Vol. 374, p. 635-45.
  206. Van Os J., Linscott R. J., Myin-Germeys I. et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder//Psychol. Med., 2009, Vol. 39, p. 179-195
  207. Vollmer-Larsen A., Jacobsen T.B., Hemmingsen R., Parnas J. Schizoaffective disorderthe ratability of its clinical diagnostic use//Acta Psychiatr Scand, 2006, Vol. 113, p. 402-407
  208. VolkowN.D., Wolf A. P, BrodieJ.D. et al. Brain interactions in chronic schizophrenics under resting and activation conditions//Schizophr. Res., 1988, Vol. 1, p. 47-53.
  209. Weinberger D. R. Implications of normal brain development for the pathogenesis of schizophrenia//Arch. Gen. Psychiatry, 1987, Vol. 44, p. 660-669.
  210. Weinberger D. R., Berman К. E, Suddath F. et al. Evidence of dysfuncion of a pefrontallimbic network in schizophrenia: a magnetic resonance imaging and regional cerebral flow of discordant twins//Am.J. Psychiatry, 1992, Vol. 149, p. 890-897.
  211. Wible C.G., Preus A.P., Hashimoto R. A congnitive neuroscience view of schizophrenic symptoms: abnormal activation of a system for social perception and communication//Brain Imaging Behav, 2009, Vol. 3, № 1, p. 85-110.
  212. Wildenauer D.B., Schwab S.G., Maier W et al. Do schizophrenia and affective disorder share succeptibility genes?//Schizophr. Res., 1999, Vol. 39, p. 107-111.
  213. Williams N.M., O’Donovan M.C., Owen M.J. Chromosomal 22 deletion syndrome and schizophrenia//Int. Rev. Neurobiology, 2006, Vol. 73, p. 1-27.
  214. Woods S. W., Addington J., Cadenhead K. S. et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study//Schizophr. Bull., 2009, Vol. 35, p. 894-908.
  215. Wright I. C., Rabe-Hesketh S., Woodruff P. W. et al. Meta-analysis of regional brain volumes in schizophrenia//Am.J. Psychiatry, 2000, Vol. 157, № 1, p. 16-25.
  216. Yung AR, McGorry PD. Prediction of psychosis: setting the stage//Br. J. Psychiatry, 2007, Vol. 51, S1-S8.
  217. Yung A. R., Klosterkotter J., Cornblatt B., Scgultze-Lutter F. At-risk mental state and prediction./The recognition and management of early psychosis/eds. H.J. Jackson, P. D. McGorry/Cambridge University Press, 2010, p. 83-105.
Редактор:
Еще статьи
  1. Анализ побочных эффектов

    Сравнительный анализ переносимости пролонгированного рисперидона и оланзапина выявил в целом некоторые ожидаемые различия в спектре…

  2. Анализ динамики социального функционирования пациентов в процессе исследования

    Для оценки влияния сравниваемых препаратов на социальное функционирование («социально полезная деятельность, включая работу и учебу»,…

  3. Анализ динамики психопатологической симптоматики

    В группе рисперидона максимальная редукция суммарного балла по шкале PANSS наблюдалась на 25-й неделе и…

Disqus Comments Loading...